Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Summary not available.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) and Mapi Pharma announced the presentation of recent clinical findings regarding GA Depot at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston from April 22-27, 2023. The pivotal Phase III clinical trial analyzes the efficacy and safety of GA Depot, a long-acting glatiramer acetate for treating relapsing forms of multiple sclerosis (RMS). Viatris emphasizes its commitment to improving healthcare access for MS patients through innovative solutions. The poster session details include research results to be presented on April 24, 2023, from 5:30 to 6:30 p.m. EST.
Viatris is dedicated to providing high-quality medicines globally, with a portfolio of over 1,400 approved molecules across various therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2023 financial results on May 8, 2023, before the markets open. CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast at investor.viatris.com or by calling 800-579-2543. A replay will also be available on their website. Founded in November 2020, Viatris focuses on providing access to medicines globally. The company operates in over 165 countries and boasts a portfolio of more than 1,400 approved medicines across a wide range of therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) has collaborated with the American College of Cardiology to launch the "Health Equity and Social Determinants of Health in NCDs" course on the NCD Academy, coinciding with World Health Day. This initiative aims to equip healthcare professionals with resources to tackle non-communicable diseases (NCDs), which account for over 70% of global deaths. The program is part of Viatris' commitment to health equity, supporting its goal to educate 100 million patients by 2025. Launched in 2020, the NCD Academy now offers nearly comprehensive training on various NCDs, addressing mental health and advocacy as well. The course rollout started in April, highlighting the importance of equitable healthcare for vulnerable communities.
Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith as its new CEO, effective April 1, 2023, as the company prepares to advance its Phase 2 strategic plan in 2024. Smith, a seasoned healthcare executive with over 35 years of experience, has been on Viatris' Board since December 2022 and previously held leadership roles at Celgene Corporation and BioAtla, Inc. The board believes Smith's extensive expertise in building and managing complex organizations will be beneficial for Viatris' growth. Former CEO Michael Goettler will assist during the transition before his departure, after having led the company through its initial phase.
Viatris Inc. (NASDAQ: VTRS) has reported meeting its 2022 adjusted guidance, with total revenues reaching $16.263 billion, despite the negative impact of the Biosimilars Transaction and acquired IPR&D. The company confirmed a 2023 revenue growth outlook compared to 2022, excluding the full-year effects of the biosimilars. It increased shareholder returns through $250 million in share repurchases and declared a quarterly dividend of $0.12 per share. Moreover, Viatris paid down approximately $3.3 billion in debt in 2022, contributing to a total reduction of $5.4 billion since 2021, while remaining on track with planned divestitures.
Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full year 2022 financial results on February 27, before U.S. markets open. The announcement will be followed by a webcast at 8:30 a.m. ET on the same day, featuring insights from CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula. The public can access the live call through investor.viatris.com or by phone. Founded in November 2020, Viatris combines expertise in medicine distribution and sustainability, providing over 1,400 approved molecules in more than 165 countries.
Viatris shares the inspiring journey of Matt Klein, its senior director of global corporate communications, who began running marathons after being inspired by his sister in 2004. Since then, he has completed over 70 marathons and aims to run in all 50 U.S. states.
After the loss of his father in 2018, he took on a 200-mile run to honor him and has participated in three 200-mile races within four months. Klein has raised over $100,000 for charity through his running endeavors, highlighting the importance of community and resilience.
Summary not available.